#	Pagina
attuale pagina	/open-h2020/projects/209448/index.html

Opendata, web and dolomites

Mofina

Mobile Filovirus Nucleic Acid Test – Sofia ref.: 115848

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

Mofina project word cloud

Explore the words cloud of the Mofina project. It provides you a very rough idea of what is the project "Mofina" about.

human cartridges validation reg sampling mobile material prototypic 2015 instrumentation hiv alere filovirus april trade preparation kit combining reducing nat ebola genera complete rt simultaneously fast marburgvirus laboratory capillary virus technologies ce venous detect nucleic proposing advantage species until detection molecular additional assay safe purpose expanded deg min operator realstar ready instrument mark format cartridge simplify ivd workflow point screening sensitive care rapid logistics safely storage integration alone platform samples sites altona system inmi 20 45 rna time manufactured commercial acid starts infrastructure pcr stand acute infection march bnitm pan utilize filo verification designed risk diagnostics poc disposable central proven blood

Project "Mofina" data sheet

The following table provides information about the project.

Coordinator	Department of Health Organization address address: Quarry House, Quarry Hill city: Leeds postcode: LS2 7UE website: www.dh.gov.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Project website	https://www.imi.europa.eu/projects-results/project-factsheets/mofina
Total cost	4˙398˙252 €
EC max contribution	1˙162˙622 € (26%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2014-02-single-stage
Funding Scheme	IMI2-RIA
Starting year	2015
Duration (year-month-day)	from 2015-02-01 to 2017-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	Department of Health Department of Health Organization address address: Quarry House, Quarry Hill city: Leeds postcode: LS2 7UE website: www.dh.gov.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (Leeds)	coordinator	332˙460.00
2	ALTONA DIAGNOSTICS GMBH ALTONA DIAGNOSTICS GMBH Organization address address: MORKENSTRASSE 12 city: HAMBURG postcode: 22767 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	394˙178.00
3	BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN Organization address address: BERNHARD NOCHT STRASSE 74 city: HAMBURG postcode: 20359 website: www.bni.uni-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	217˙992.00
4	ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO Organization address address: Via Portuense, 292 city: ROMA postcode: 149 website: www.inmi.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	217˙992.00
5	ALERE TECHNOLOGIES GMBH ALERE TECHNOLOGIES GMBH Organization address address: LOBSTEDTER STR 103 105 city: JENA postcode: 7749 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (JENA)	participant	0.00
6	FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS Organization address address: CAMPUS BIOTECH, CHEMIN DES MINES 9 city: GENEVE postcode: 1202 website: http://www.finddiagnostics.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (GENEVE)	participant	0.00

Map

Project objective

We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics platform. The purpose of this project is to utilize existing and proven PCR assay(s) designed for laboratory use and to take advantage of the Alere™ q point of care molecular instrument and cartridge design to simplify Ebola testing so that molecular testing can be expanded to sites beyond which high end laboratory infrastructure is not available while simultaneously greatly reducing infection risk for the test operator. The project aims for the fast development of a point of care Nucleic Acid Test (POC-NAT) system for filovirus specific RNA, from human sample material, especially from blood samples. The POC-NAT system will have the following features: 1. Field proven stand alone, mobile and easy to use instrumentation 2. ready to use cartridge, safely disposable nucleic acid test format with integrated sample preparation 3. assay for specific detection of RNA of all known species from the virus genera Ebola- and Marburgvirus . 4. process duration from sampling to result less than 45 min 5. no additional equipment and no logistics and storage at -20°C needed The POC-NAT is based on two already existing technologies: The instrument platform “Alere™q complete” developed and manufactured by Alere , an instrument for POC diagnostics recently used p.e. for Alere´s HIV-1/2 Detect cartridges, and altona Diagnostics´ RealStar® Filovirus RT-PCR kit 1.0, a commercial central laboratory real-time PCR test. The project partner aim for having the integration of platform and assay as a prototypic system completed until end of March 2015. The verification and validation of the workflow starts April 2015 at altona Diagnostics, BNITM and INMI. The aim of this project phase is to finally CE IVD mark the test system

Publications

List of publications.
year	authors and title	journal	last update
2015	Chris A Whitehouse, Sina Bavari, Mark D Perkins United States FDAâ€™s emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future published pages: 1231-1235, ISSN: 1473-7159, DOI: 10.1586/14737159.2015.1077117	Expert Review of Molecular Diagnostics 15/10	2019-07-24
2015	Mark D Perkins, Mark Kessel What Ebola tells us about outbreak diagnostic readiness published pages: 464-469, ISSN: 1087-0156, DOI: 10.1038/nbt.3215	Nature Biotechnology 33/5	2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOFINA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOFINA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors